



**AUSTRALIA BIOTECH
INVEST & PARTNERING 2018**
Connecting capital with innovation

Tuesday 30 October
Sofitel Melbourne on Collins
ausbiotechinvestment.com.au

#AusBioInv



Company profile

Race Oncology is a specialty pharmaceutical company pursuing late stage drug assets overlooked by big pharma. Our first asset is a chemotherapy agent called Bisantrene, which was the subject of more than 40 phase II studies, before it was lost in a series of big pharma mergers during the 1990s. We intend to complete final clinical development and seek regulatory approval in the US for relapsed/refractory Acute Myeloid Leukemia (AML), while making the drug available to doctors and patients under a Named Patient Program in certain countries.

Speaker Profile

Peter Molloy, Managing Director & Chief Executive Officer, Race Oncology Ltd



Peter Molloy is the Managing Director and CEO of Race Oncology. His background includes 18 years in the pharmaceutical industry, including Managing Director of Pharmacia Australia and Vice President Strategic Marketing for Pharmacia in Asia/Pacific and Latin America. Subsequently, he served as CEO of three biotech companies prior to Race Oncology. Overall, during his career, he has managed eight biotechnology or pharmaceutical operations, launched 23 pharmaceutical products, including Betadine® OTC products, Somac® (pantoprazole) and Doryx® (doxycycline controlled-release), and executed 40 international licensing or distribution deals. He holds a BSc and MBA and is also a Fellow of the Australian Institute of Company Directors.